SanBio Company Limited

4592.T
Biotechnology
2026/03/02 Updated
Market Cap: $1.1B (¥176.2B)
Stock Price: $14.47 (¥2,258)
Exchange Rate: 1 USD = ¥156.01

Stock Price Chart

2026/03/02 Updated
0.00
PER (Price Earnings Ratio)
vs Industry Avg: -9.6
330.46
PBR (Price to Book Ratio)
vs Industry Avg: +329.2
0.00%
Dividend Yield
vs Industry Avg: -2.95%

Price Trend

2026/03/02 Updated
Short-term
5-Day MA
+2.95%
Near-term
25-Day MA
+11.22%
Mid-term
75-Day MA
+14.41%
Long-term
200-Day MA
-7.35%

Price & Trading Details

2026/03/02 Updated

PRICE

Previous Close ¥2,154
Open ¥2,166
High ¥2,259
Low ¥2,155
Close ¥2,258

TRADING

Volume 951,500
Average Volume 1,816,753
Turnover ¥21億
Min. Purchase ¥225,800

Analyst Recommendations 5 analysts

Updated 2026/03/01
Strong Buy
0
Buy
0
Hold
3
3
Sell
2
2
Strong Sell
0
Target Price (Mean)
¥2,050
None
¥2,900
High
¥2,000
Median
¥1,250
Low
+27% vs Current Price
This information is based on market data from third-party data providers and is for reference only. Investment decisions are your own responsibility.

Shareholder Composition

Updated 2026/03/01
24.0%
Insider Holdings
6.9%
Institutional
69.1%
Public Float
30
Institutional Holders
Insider Holdings 24.0%
Institutional 6.9%
Public Float 69.1%

Major Holders

Updated 2026/03/01
Institution Ownership Shares Change
iShares Trust-iShares Core MSCI EAFE ETF
0.51%
397.1K 0.00%
iShares Trust-iShares MSCI EAFE Small-Cap ETF
0.26%
205.6K 0.00%
SPDR INDEX SHARES FUNDS-SPDR Portfolio Developed World ex-US ETF
0.24%
187.5K 0.00%
iShares Trust-iShares Core MSCI International Developed Markets ETF
0.09%
72.3K 0.00%
College Retirement Equities Fd.-College Retirement Equities Fd. - Tota
0.05%
41.2K 0.00%
SPDR INDEX SHARES FUNDS-SPDR(R) S&P(R) International Small Cap ETF
0.03%
23.5K -1.26%

Financial Performance

2026/03/01 Updated

No financial data available

Latest IR Information

Latest News (5 items)

Company Information

English Name SanBio Company Limited
Japanese Name サンバイオ(株)
Stock Code 4592.T (JPX)
Sector / Industry Healthcare / Biotechnology
Website https://www.sanbio.com
Employees 29

About

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Data provided by Yahoo Finance